Yu Cai
Publication Activity (10 Years)
Years Active: 2018-2024
Publications (10 Years): 7
Publications (10 Years): 7
Publications
- Chongmei Huang, Yannan Jia, Jun Yang, Yu Cai, Yin Tong, Huiying Qiu, Kun Zhou, Xinxin Xia, Ying Zhang, Chang Shen, Liping Wan, Xian-Min Song
- Jiahua Niu, Huiying Qiu, Fang Xiang, Lin Zhu, Jun Yang, Chongmei Huang, Kun Zhou, Yin Tong, Yu Cai, Baoxia Dong, Yuan Lu, Xuedong Sun, Liping Wan, Xueying Ding, Haopeng Wang, Xian-Min Song
- Jiahua Niu, Huiying Qiu, Fang Xiang, Lin Zhu, Jun Yang, Chongmei Huang, Kun Zhou, Yin Tong, Yu Cai, Baoxia Dong, Yuan Lu, Xuedong Sun, Liping Wan, Xueying Ding, Haopeng Wang, Xian-Min Song
- Xi Sun, Jun Yang, Yu Cai, Liping Wan, Chongmei Huang, Huiying Qiu, Yin Tong, Xiaowei Xu, Kun Zhou, Xueying Ding, Xian-Min Song
- Jae-Sook Ahn, TaeHyung Kim, Sung-Hoon Jung, Seo-Yeon Ahn, Seung-Yeon Jung, Ga-Young Song, Mihee Kim, Deok-Hwan Yang, Je-Jung Lee, SeungHyun Choi, Ja-Yeon Lee, Seong-Kyu Park, Joon-Ho Moon, Hui-Young Lee, Kyoung Ha Kim, Yu Cai, Seong Yoon Yi, Igor Novitzky-Basso, Zhaolei Zhang, Hyeoung-Joon Kim, Dennis Dong Hwan Kim
- Xiaoqian Xu, Jun Yang, Yu Cai, Su Li, Jiahua Niu, Kun Zhou, Ying Jiang, Xiaowei Xu, Chang Shen, Chongmei Huang, Huiying Qiu, Daolin Wei, Mei Kang, Yin Tong, Zheng Wei, Peng Liu, Liping Wan, Xian-Min SongLow dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood. Bone marrow transplantation 56 (3) (2020)
- Jun Yang, Jieling Jiang, Yu Cai, Su Li, Liping Wan, Jun Zhu, Huixia Liu, Shan Shao, Haitao Bai, Chun Wang, Xianmin SongLow-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone marrow transplantation 54 (7) (2018)